bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
150 hedge funds and large institutions have $78.4M invested in bluebird bio in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 48 reducing their positions, and 30 closing their positions.
0.64% less ownership
Funds ownership: 2.67% → 2.04% (-0.64%)
5% less funds holding
Funds holding: 158 → 150 (-8)
23% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 48
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
40% less call options, than puts
Call options by funds: $758K | Put options by funds: $1.25M
41% less capital invested
Capital invested by funds: $134M → $78.4M (-$55.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.01M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$444K |
| 3 |
State Street
Boston,
Massachusetts
|
+$371K |
| 4 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$353K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$333K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$9.87M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.61M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.19M |
| 5 |
Two Sigma Investments
New York
|
-$1.87M |
BLUE Hedge Fund Activity: Q2 2024 in Review
150 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2024, worth a combined $78.4M — down 41% from $134M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of BLUE and 23 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 37 added.
The largest buyer was AQR Capital Management, adding an estimated $1.01M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $9.87M sold.
- 150 institutional investors held bluebird bio (BLUE) as of Q2 2024, down from 158 in Q1 2024.
- Funds reported $78.4M of bluebird bio stock for Q2 2024, down 41% quarter-over-quarter.
- 23 funds opened new bluebird bio positions in Q2 2024 and 30 closed out, a net change of -7 holders.
- The largest bluebird bio buyer in Q2 2024 was AQR Capital Management, an estimated $1.01M added.
- The largest bluebird bio seller in Q2 2024 was Granahan Investment Management, an estimated $9.87M sold.
Based on aggregated 13F filings for Q2 2024.